A Second Course of High-Dose Melphalan and Auto-SCT for the Treatment of Relapsed AL Amyloidosis

Bone Marrow Transplantation - United Kingdom
doi 10.1038/bmt.2010.239
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

An Overview of the Use of High-Dose Melphalan With Autologous Stem Cell Transplantation for the Treatment of AL Amyloidosis

Bone Marrow Transplantation
TransplantationHematology
2001English

Second Allogeneic Stem-Cell Transplantation (SCT) From a Different Donor for the Treatment of Relapsed AML and MDS After a Previous Allogeneic SCT

Biology of Blood and Marrow Transplantation
TransplantationHematology
2013English

Matched-Pair Analysis to Compare the Outcomes of a Second Salvage Auto-SCT to Systemic Chemotherapy Alone in Patients With Multiple Myeloma Who Relapsed After Front-Line Auto-SCT

Bone Marrow Transplantation
TransplantationHematology
2012English

Trends in Day 100 and 2-Year Survival After Auto-SCT for AL Amyloidosis: Outcomes Before and After 2006

Bone Marrow Transplantation
TransplantationHematology
2010English

Auto-SCT for AML in Second Remission: CALGB Study 9620

Bone Marrow Transplantation
TransplantationHematology
2009English

Primary Central Nervous System Lymphoma: Implication of High-Dose Chemotherapy Followed by Auto-SCT

Bone Marrow Transplantation
TransplantationHematology
2011English

Current Treatment of AL Amyloidosis

Haematologica
Hematology
2009English

Melphalan, Lenalidomide and Dexamethasone for the Treatment of Immunoglobulin Light Chain Amyloidosis: Results of a Phase II Trial

Haematologica
Hematology
2012English

Prognostic Value of Comorbidity for Auto-SCT Eligibility and Outcome in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Bone Marrow Transplantation
TransplantationHematology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy